INTRODUCTION
The current generation of MRI contrast agents is mainly limited by a lack of multiplexed imaging, relatively low sensitivity, as well as a lack of functional imaging or sensing capability. Categorized by their effect on the image, “positive” contrast agents [1], such as gadolinium chelates, shorten relaxation times and “brighten” the local environments affected by these agents [2], whereas “negative” contrast agents, such as (ultrasmall) superparamagnetic iron oxides (USPIO, SPIO), function largely by shortening relaxation times and “darken” the image [3]. These monochromatic responses are in sharp contrast to the rich, multi-colored palette available with optical imaging contrast agents [4].